Gabapentin and Graft versus host disease - a phase IV clinical study of FDA data

Summary:

Graft versus host disease is reported as a side effect among people who take Gabapentin (gabapentin), especially for people who are female, 60+ old, also take Bactrim, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Graft versus host disease when taking Gabapentin. It is created by eHealthMe based on reports of 313,421 people who have side effects when taking Gabapentin from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 322,983 Gabapentin users. Check the latest studies of Gabapentin.

What is Graft versus host disease?

Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body) is found to be associated with 498 drugs and 642 conditions by eHealthMe. Check the latest studies of Graft versus host disease.

On Jul, 18, 2026

313,421 people reported to have side effects when taking Gabapentin.
Among them, 85 people (0.03%) have Graft versus host disease.

Could Gabapentin cause Graft versus host disease?

Among these 85 people:

What is the gender of people who have Graft versus host disease when taking Gabapentin? *

female: 57.97 %
male: 42.03 %

What is the age of people who have Graft versus host disease when taking Gabapentin? *

What are other drugs people take besides Gabapentin? *

What are other side effects people have besides Graft versus host disease? *

Fatigue (feeling of tiredness): 24 people, 28.24%
Rashes (redness): 18 people, 21.18%
Pain In Extremity: 15 people, 17.65%
Muscle Spasms (muscle contraction): 13 people, 15.29%
Nausea (feeling of having an urge to vomit): 12 people, 14.12%
Weakness: 12 people, 14.12%
Pneumonia: 12 people, 14.12%
Dizziness: 11 people, 12.94%
Fever: 11 people, 12.94%
Dry Mouth: 11 people, 12.94%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 21 people, 24.71%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 9 people, 10.59%
Neuropathy Peripheral (surface nerve damage): 8 people, 9.41%
Glaucoma (increased fluid pressure in the eye with vision loss): 5 people, 5.88%
Stress And Anxiety: 5 people, 5.88%
Lymphoma (cancer that begins in immune system cells): 5 people, 5.88%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 4 people, 4.71%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 4 people, 4.71%
Multiple Myeloma (cancer of the plasma cells): 3 people, 3.53%
Nerve Injury: 3 people, 3.53%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and have Graft versus host disease?

- Check whether Graft versus host disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gabapentin:

Gabapentin (322,983 reports)

Browse all side effects of Gabapentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Graft versus host disease:

Graft versus host disease (498 drugs)

Browse all the conditions that are associated with Graft versus host disease:

Graft versus host disease (642 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.